SOPHiA Genetics focuses on external growth

Please login or
register
18.06.2018
DNA

SOPHiA Genetics acquired the French-based tech company Interactive Biosoftware (IBS). IBS created the most used decision support software for clinical genomic data interpretation.

Last September SOPHiA Genetics closed a CHF30million financing round. In February 2018 the company hired a new CFO, an indication fur further growth plans which in the end may lead to an IPO. With the acquisition of IBS, SOPHiA Genetics is taking an important step in this direction.

The software of IBS called Alamut is currently deployed in over 450 hospitals and is highly complementary to SOPHiA Genetics’ offering. This technology (SOPHiA) has already helped to analyze over 200,000 patients across the world and is currently being used in over 480 hospitals across 60 countries.

Interactive Biosoftware’s expertise and teams will join SOPHiA Genetics’ workforce. A seamless onboarding will ensure Alamut users’ experience. “Interactive Biosoftware has been highly successful in providing powerful technology for experts with complex genomic interpretation needs. It is great to join SOPHiA Genetics unique approach and position to accelerate Data-Driven Medicine’s adoption.” – André Blavier CEO & Founder at Interactive Biosoftware.

“We are very excited about the acquisition of Interactive Biosoftware. Both SOPHiA AI and Alamut are technologies trusted by the healthcare community and focus on patient-centric innovation. The addition of Alamut marks a big step in our aim to help clinicians better diagnose patients equally. With a community of now over 900 teaching hospitals using our technologies we are in a unique position to connect clinicians and enable them to share knowledge.” - Jurgi Camblong, CEO & Co-founder at SOPHiA Genetics.

(Press release / SK)

0Comments

More news about

Sophia Genetics SA

Company profiles on startup.ch

Sophia Genetics SA

rss